
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Now that any US adult aged ≥18 years can receive a COVID-19 booster dose, have they actually started getting it? According to the US






